Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773819 | 1.00 | DGAT1 (0.41) | DGAT1PIK3CAHCRTR1HCRTR2OPRK1 | |
| SCHEMBL20129131 | 0.81 | DGAT1 (0.37) | DGAT1HCRTR1HCRTR2 | |
| SCHEMBL20120851 | 0.81 | DGAT1 (0.37) | DGAT1HCRTR1HCRTR2 | |
| SCHEMBL29547899 | 0.81 | DGAT1 (0.37) | DGAT1HCRTR1HCRTR2 | |
| SCHEMBL27136582 | 0.81 | DGAT1 (0.38) | DGAT1HCRTR1HCRTR2OPRK1KCNH2 | |
| SCHEMBL29547438 | 0.81 | DGAT1 (0.38) | DGAT1HCRTR1HCRTR2OPRK1KCNH2 | |
| SCHEMBL20129259 | 0.81 | DGAT1 (0.38) | DGAT1HCRTR1HCRTR2OPRK1KCNH2 | |
| SCHEMBL27098324 | 0.81 | DGAT1 (0.43) | DGAT1HCRTR1HCRTR2OPRK1KCNH2 | |
| SCHEMBL20214011 | 0.79 | DGAT1 (0.37) | DGAT1HCRTR1HCRTR2 | |
| SCHEMBL27098384 | 0.79 | DGAT1 (0.40) | DGAT1HCRTR1HCRTR2OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | DGAT1 4519/4885PIK3CA 2277/4885HCRTR1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.